Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Alex Van Ry"'
Variant-proof high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways
Autor:
Matthew Gagne, Barbara J. Flynn, Christopher Cole Honeycutt, Dillon R. Flebbe, Shayne F. Andrew, Samantha J. Provost, Lauren McCormick, Alex Van Ry, Elizabeth McCarthy, John-Paul M. Todd, Saran Bao, I-Ting Teng, Shir Marciano, Yinon Rudich, Chunlin Li, Shilpi Jain, Bushra Wali, Laurent Pessaint, Alan Dodson, Anthony Cook, Mark G. Lewis, Hanne Andersen, Jiří Zahradník, Mehul S. Suthar, Martha C. Nason, Kathryn E. Foulds, Peter D. Kwong, Mario Roederer, Gideon Schreiber, Robert A. Seder, Daniel C. Douek
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-13 (2024)
Abstract SARS-CoV-2 has the capacity to evolve mutations that escape vaccine- and infection-acquired immunity and antiviral drugs. A variant-agnostic therapeutic agent that protects against severe disease without putting selective pressure on the vir
Externí odkaz:
https://doaj.org/article/398a2dfd9ac6483f881f1a81f6f17840
Autor:
Moonsup Jeong, Sagar B. Kudchodkar, Areum Gil, Bohyun Jeon, Gee Ho Park, Youngran Cho, Hyojin Lee, Mi Sun Cheong, Wonil Kim, Yun-Ho Hwang, Jung-Ah Lee, Heeji Lim, Mi Young Kim, Emran O. Lallow, Tej Brahmbhatt, Stephen A. Kania, Nandita C. Jhumur, Jerry W. Shan, Jeffrey D. Zahn, David I. Shreiber, Jonathan P. Singer, Hao Lin, Erin K. Spiegel, Laurent Pessaint, Maciel Porto, Alex Van Ry, Danielle Nase, Swagata Kar, Hanne Andersen, Ian Tietjen, Joel Cassel, Joseph M. Salvino, Luis J. Montaner, Young K. Park, Kar Muthumani, Christine C. Roberts, Joel N. Maslow
Publikováno v:
Frontiers in Virology, Vol 2 (2022)
SARS-CoV-2 is the third pathogenic coronavirus to emerge since 2000. Experience from prior outbreaks of SARS-CoV and MERS-CoV has demonstrated the importance of both humoral and cellular immunity to clinical outcome, precepts that have been recapitul
Externí odkaz:
https://doaj.org/article/c73deb36ca654fa2815416d4cd1e4dd1
Autor:
Daniel Y Zhu, Matthew J Gorman, Dansu Yuan, Jingyou Yu, Noe B Mercado, Katherine McMahan, Erica N Borducchi, Michelle Lifton, Jinyan Liu, Felix Nampanya, Shivani Patel, Lauren Peter, Lisa H Tostanoski, Laurent Pessaint, Alex Van Ry, Brad Finneyfrock, Jason Velasco, Elyse Teow, Renita Brown, Anthony Cook, Hanne Andersen, Mark G Lewis, Douglas A Lauffenburger, Dan H Barouch, Galit Alter
Publikováno v:
PLoS Biology, Vol 20, Iss 5, p e3001609 (2022)
Despite the rapid creation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccines, the precise correlates of immunity against severe Coronavirus Disease 2019 (COVID-19) are still unknown. Neutralizing antibodies represent a robust s
Externí odkaz:
https://doaj.org/article/4d1be3554a1648f7a95b8e4694bcb0af
Autor:
Maggie Gu, Jonathan L. Torres, Yijia Li, Alex Van Ry, Jack Greenhouse, Shannon Wallace, Chi-I Chiang, Laurent Pessaint, Abigail M. Jackson, Maciel Porto, Swagata Kar, Yuxing Li, Andrew B. Ward, Yimeng Wang
Publikováno v:
Emerging Microbes and Infections, Vol 10, Iss 1, Pp 2016-2029 (2021)
A COVID-19 vaccine that can give early protection is needed to eliminate the viral spread efficiently. Here, we demonstrate the development of a nanoparticle vaccine candidate, REVC-128, in which multiple trimeric spike ectodomains with glycine (G) a
Externí odkaz:
https://doaj.org/article/b289bfcf3ee446abbb5dcc10d9157977
Autor:
Kai Wu, Ian N. Moore, Bridget Bart, John-Paul Todd, Elham Bayat Mokhtari, Gabriela S. Alvarado, Swagata Kar, Jaclyn Wear, Manjari Sriparna, Kathryn E. Foulds, Matthew Gagne, Mario Roederer, Kizzmekia S. Corbett, Seyhan Boyoglu-Barnum, Darin K. Edwards, Barbara J. Flynn, Katelyn Steingrebe, Adrian B. McDermott, Samantha J. Provost, Angela Choi, Shayne F. Andrew, Eli Boritz, Sayda Elbashir, Zackery Flinchbaugh, Timothy S. Johnston, Martha Nason, Sarah O’ Connell, Anthony Cook, Bianca M. Nagata, Mahnaz Minai, Prakriti Mudvari, Mark G. Lewis, Andrew Pekosz, Amy R. Henry, Farida Laboune, Dillon R. Flebbe, Becky Chang, Alex Van Ry, Nancy J. Sullivan, Juan I. Moliva, Saule T. Nurmukhambetova, Laurent Pessaint, Lilin Lai, Matthew A. Koch, Barney S. Graham, Hanne Leth Andersen, Maciel Porto, Kevin W. Bock, Daniel C. Douek, Anne P. Werner, Mehul S. Suthar, Evan Lamb, Alan Dodson, Andrea Carfi, Robert A. Seder
Publikováno v:
Nature Immunology. 22:1306-1315
B.1.351 is the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant most resistant to antibody neutralization. We demonstrate how the dose and number of immunizations influence protection. Nonhuman primates received two doses of 30 or
Autor:
Jonathan L. Torres, Shannon Wallace, Abigail M. Jackson, Maciel Porto, Chi-I Chiang, Alex Van Ry, Yuxing Li, Yimeng Wang, Jack Greenhouse, Yijia Li, Andrew B. Ward, Laurent Pessaint, Maggie Gu, Swagata Kar
Publikováno v:
Emerging Microbes & Infections
article-version (VoR) Version of Record
article-version (VoR) Version of Record
A COVID-19 vaccine that can give early protection is needed to eliminate the viral spread efficiently. Here, we demonstrate the development of a nanoparticle vaccine candidate, REVC-128, in which multiple trimeric spike ectodomains with glycine (G) a
Autor:
Lisa H. Tostanoski, Alex Van Ry, Alex Lee Zhu, Elyse Teow, Abishek Chandrashekar, Shivani A. Patel, Jinyan Liu, Lauren Peter, Anthony L. Cook, Jake Yalley-Ogunro, Galit Alter, Dan H. Barouch, Mark G. Lewis, Carolin Loos, Gabriel Dagotto, Jingyou Yu, Makda S. Gebre, Mehtap Cabus, Felix Nampanya, Zhenfeng Li, Renita Brown, Douglas A. Lauffenburger, Catherine Jacob-Dolan, Esther A. Bondzie, Kelvin Blade, Laurent Pessaint, Noe B. Mercado, Hanne Andersen, Katherine McMahan, Caroline Atyeo
Publikováno v:
Nature
Recent studies have reported the protective efficacy of both natural1 and vaccine-induced2–7 immunity against challenge with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in rhesus macaques. However, the importance of humoral and cel
Autor:
Albert To, Teri Ann S. Wong, Michael M. Lieberman, Karen Thompson, Aquena H. Ball, Laurent Pessaint, Jack Greenhouse, Nisrine Daham, Anthony Cook, Brandon Narvaez, Zack Flinchbaugh, Alex Van Ry, Jake Yalley-Ogunro, Hanne Andersen Elyard, Chih-Yun Lai, Oreola Donini, Axel T. Lehrer
Publikováno v:
ACS infectious diseases. 8(4)
FDA-approved and emergency use-authorized vaccines using new mRNA and viral-vector technology are highly effective in preventing moderate to severe disease; however, information on their long-term efficacy and protective breadth against severe acute
Autor:
Abishek Chandrashekar, Jingyou Yu, Katherine McMahan, Catherine Jacob-Dolan, Jinyan Liu, Xuan He, David Hope, Tochi Anioke, Julia Barrett, Benjamin Chung, Nicole P. Hachmann, Michelle Lifton, Jessica Miller, Olivia Powers, Michaela Sciacca, Daniel Sellers, Mazuba Siamatu, Nehalee Surve, Haley VanWyk, Huahua Wan, Cindy Wu, Laurent Pessaint, Daniel Valentin, Alex Van Ry, Jeanne Muench, Mona Boursiquot, Anthony Cook, Jason Velasco, Elyse Teow, Adrianus C.M. Boon, Mehul S. Suthar, Neharika Jain, Amanda J. Martinot, Mark G. Lewis, Hanne Andersen, Dan H. Barouch
Publikováno v:
bioRxiv
BackgroundThe rapid spread of the SARS-CoV-2 Omicron (B.1.1.529) variant, including in highly vaccinated populations, has raised important questions about the efficacy of current vaccines. Immune correlates of vaccine protection against Omicron are n
Autor:
Matthew Gagne, Juan I. Moliva, Kathryn E. Foulds, Shayne F. Andrew, Barbara J. Flynn, Anne P. Werner, Danielle A. Wagner, I-Ting Teng, Bob C. Lin, Christopher Moore, Nazaire Jean-Baptiste, Robin Carroll, Stephanie L. Foster, Mit Patel, Madison Ellis, Venkata-Viswanadh Edara, Nahara Vargas Maldonado, Mahnaz Minai, Lauren McCormick, Christopher Cole Honeycutt, Bianca M. Nagata, Kevin W. Bock, Caitlyn N. M. Dulan, Jamilet Cordon, John-Paul M. Todd, Elizabeth McCarthy, Laurent Pessaint, Alex Van Ry, Brandon Narvaez, Daniel Valentin, Anthony Cook, Alan Dodson, Katelyn Steingrebe, Dillon R. Flebbe, Saule T. Nurmukhambetova, Sucheta Godbole, Amy R. Henry, Farida Laboune, Jesmine Roberts-Torres, Cynthia G. Lorang, Shivani Amin, Jessica Trost, Mursal Naisan, Manjula Basappa, Jacquelyn Willis, Lingshu Wang, Wei Shi, Nicole A. Doria-Rose, Adam S. Olia, Cuiping Liu, Darcy R. Harris, Andrea Carfi, John R. Mascola, Peter D. Kwong, Darin K. Edwards, Hanne Andersen, Mark G. Lewis, Kizzmekia S. Corbett, Martha C. Nason, Adrian B. McDermott, Mehul S. Suthar, Ian N. Moore, Mario Roederer, Nancy J. Sullivan, Daniel C. Douek, Robert A. Seder
SummarySARS-CoV-2 Omicron is highly transmissible and has substantial resistance to antibody neutralization following immunization with ancestral spike-matched vaccines. It is unclear whether boosting with Omicron-specific vaccines would enhance immu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bf75ae434882f0dd8baa7a19d8b7db69
https://doi.org/10.1101/2022.02.03.479037
https://doi.org/10.1101/2022.02.03.479037